Filipe A. Moura, M.D.,Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetes Mellitus, Type 2 | 9 | 2024 | 12293 | 0.650 |
Why?
|
Myocardial Infarction | 8 | 2023 | 11891 | 0.580 |
Why?
|
Dyslipidemias | 3 | 2019 | 895 | 0.490 |
Why?
|
Insulin Resistance | 4 | 2019 | 3959 | 0.470 |
Why?
|
Insulin | 5 | 2019 | 6597 | 0.460 |
Why?
|
Endothelium, Vascular | 4 | 2021 | 4433 | 0.450 |
Why?
|
Weight Loss | 2 | 2024 | 2686 | 0.440 |
Why?
|
Periodicity | 1 | 2013 | 348 | 0.390 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2023 | 2290 | 0.330 |
Why?
|
Cardiovascular Diseases | 6 | 2024 | 15757 | 0.300 |
Why?
|
Blood Glucose | 4 | 2021 | 6381 | 0.290 |
Why?
|
Seasons | 1 | 2013 | 1522 | 0.290 |
Why?
|
Benzhydryl Compounds | 3 | 2023 | 941 | 0.280 |
Why?
|
Cholesterol, HDL | 4 | 2019 | 1817 | 0.270 |
Why?
|
Diabetes Mellitus | 2 | 2022 | 5889 | 0.250 |
Why?
|
Gastric Inhibitory Polypeptide | 2 | 2023 | 66 | 0.250 |
Why?
|
Niacin | 1 | 2014 | 119 | 0.220 |
Why?
|
Sodium-Glucose Transporter 2 | 1 | 2023 | 98 | 0.220 |
Why?
|
Triglycerides | 3 | 2024 | 2476 | 0.210 |
Why?
|
Vasodilation | 3 | 2021 | 962 | 0.210 |
Why?
|
Apolipoprotein C-III | 1 | 2024 | 209 | 0.210 |
Why?
|
Lipoproteins, HDL | 2 | 2019 | 667 | 0.190 |
Why?
|
Brazil | 5 | 2021 | 1218 | 0.190 |
Why?
|
Plaque, Atherosclerotic | 1 | 2012 | 1518 | 0.190 |
Why?
|
Anti-Obesity Agents | 1 | 2024 | 229 | 0.180 |
Why?
|
Oligonucleotides | 1 | 2024 | 588 | 0.180 |
Why?
|
Catheters | 1 | 2024 | 425 | 0.180 |
Why?
|
Hypertriglyceridemia | 1 | 2024 | 316 | 0.180 |
Why?
|
Glyburide | 1 | 2021 | 114 | 0.180 |
Why?
|
Glucosides | 2 | 2022 | 533 | 0.170 |
Why?
|
Sarcopenia | 2 | 2017 | 372 | 0.170 |
Why?
|
Vasodilator Agents | 1 | 2014 | 978 | 0.170 |
Why?
|
Hypoglycemic Agents | 3 | 2023 | 3150 | 0.170 |
Why?
|
Atherosclerosis | 2 | 2012 | 3517 | 0.170 |
Why?
|
Weight Gain | 2 | 2019 | 2347 | 0.150 |
Why?
|
Fatty Acids, Omega-3 | 2 | 2019 | 1387 | 0.150 |
Why?
|
Carotid Artery Diseases | 2 | 2021 | 883 | 0.140 |
Why?
|
Simvastatin | 1 | 2019 | 352 | 0.140 |
Why?
|
Overweight | 2 | 2019 | 2421 | 0.140 |
Why?
|
Disease Progression | 2 | 2024 | 13502 | 0.140 |
Why?
|
Coronary Artery Disease | 4 | 2024 | 6659 | 0.140 |
Why?
|
Glucose Clamp Technique | 2 | 2013 | 263 | 0.130 |
Why?
|
Risk Factors | 12 | 2024 | 74359 | 0.130 |
Why?
|
Heart Valve Diseases | 1 | 2024 | 1047 | 0.130 |
Why?
|
No-Reflow Phenomenon | 1 | 2015 | 17 | 0.130 |
Why?
|
Indoles | 1 | 2014 | 1829 | 0.130 |
Why?
|
Risk Assessment | 5 | 2024 | 24123 | 0.130 |
Why?
|
Aged | 16 | 2024 | 169152 | 0.130 |
Why?
|
Hydroxycholesterols | 1 | 2014 | 25 | 0.120 |
Why?
|
Glomerular Filtration Rate | 1 | 2023 | 2180 | 0.120 |
Why?
|
Middle Aged | 19 | 2024 | 220352 | 0.120 |
Why?
|
Brachial Artery | 1 | 2015 | 366 | 0.110 |
Why?
|
Environment Design | 1 | 2015 | 172 | 0.110 |
Why?
|
Treatment Outcome | 7 | 2024 | 65017 | 0.100 |
Why?
|
Cooking | 1 | 2015 | 311 | 0.100 |
Why?
|
Inflammation | 3 | 2019 | 10756 | 0.100 |
Why?
|
Humans | 31 | 2024 | 760621 | 0.100 |
Why?
|
Frail Elderly | 2 | 2019 | 752 | 0.100 |
Why?
|
Seafood | 1 | 2015 | 390 | 0.100 |
Why?
|
Ventricular Remodeling | 1 | 2019 | 1261 | 0.100 |
Why?
|
Age Factors | 5 | 2017 | 18416 | 0.090 |
Why?
|
Male | 19 | 2024 | 359744 | 0.090 |
Why?
|
Nonlinear Dynamics | 1 | 2013 | 494 | 0.090 |
Why?
|
Female | 19 | 2024 | 391270 | 0.090 |
Why?
|
Cholesterol, LDL | 2 | 2024 | 2420 | 0.090 |
Why?
|
Arteries | 1 | 2014 | 1126 | 0.080 |
Why?
|
Coronary Angiography | 3 | 2017 | 4563 | 0.080 |
Why?
|
Sirtuins | 1 | 2012 | 320 | 0.080 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2020 | 2128 | 0.080 |
Why?
|
Prospective Studies | 7 | 2021 | 54303 | 0.080 |
Why?
|
Hypolipidemic Agents | 2 | 2024 | 626 | 0.080 |
Why?
|
Accidents, Traffic | 1 | 2015 | 814 | 0.080 |
Why?
|
Energy Intake | 1 | 2017 | 2129 | 0.080 |
Why?
|
Body Mass Index | 2 | 2024 | 12914 | 0.080 |
Why?
|
Peripheral Arterial Disease | 2 | 2024 | 1306 | 0.080 |
Why?
|
Sex Distribution | 1 | 2013 | 2295 | 0.080 |
Why?
|
Kidney | 1 | 2023 | 7064 | 0.080 |
Why?
|
Patient Admission | 1 | 2015 | 1386 | 0.070 |
Why?
|
ROC Curve | 1 | 2015 | 3568 | 0.070 |
Why?
|
Body Composition | 1 | 2017 | 2419 | 0.070 |
Why?
|
Fasting | 1 | 2013 | 1603 | 0.070 |
Why?
|
Age Distribution | 1 | 2013 | 2893 | 0.070 |
Why?
|
Follow-Up Studies | 3 | 2019 | 39261 | 0.070 |
Why?
|
C-Reactive Protein | 2 | 2015 | 3839 | 0.070 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2019 | 3334 | 0.070 |
Why?
|
Nitric Oxide | 1 | 2015 | 2141 | 0.070 |
Why?
|
Obesity | 2 | 2024 | 12922 | 0.060 |
Why?
|
Aged, 80 and over | 6 | 2019 | 58995 | 0.060 |
Why?
|
Genome-Wide Association Study | 1 | 2024 | 12626 | 0.060 |
Why?
|
Stress, Physiological | 1 | 2011 | 1398 | 0.060 |
Why?
|
Lipids | 1 | 2015 | 3336 | 0.060 |
Why?
|
Aging | 2 | 2012 | 8651 | 0.050 |
Why?
|
Enteroendocrine Cells | 1 | 2024 | 77 | 0.050 |
Why?
|
Isoprostanes | 1 | 2022 | 19 | 0.050 |
Why?
|
Hyperglycemia | 1 | 2011 | 1380 | 0.050 |
Why?
|
Sex Factors | 2 | 2013 | 10547 | 0.050 |
Why?
|
Apolipoproteins B | 1 | 2024 | 388 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3085 | 0.050 |
Why?
|
Wounds and Injuries | 1 | 2015 | 2477 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3205 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 1 | 2024 | 17790 | 0.050 |
Why?
|
Muscle, Skeletal | 1 | 2017 | 4925 | 0.050 |
Why?
|
Oligonucleotides, Antisense | 1 | 2024 | 459 | 0.050 |
Why?
|
Receptor, Angiotensin, Type 2 | 1 | 2020 | 60 | 0.040 |
Why?
|
Delayed-Action Preparations | 1 | 2014 | 961 | 0.040 |
Why?
|
Sensitivity and Specificity | 1 | 2015 | 14660 | 0.040 |
Why?
|
Logistic Models | 4 | 2017 | 13314 | 0.040 |
Why?
|
Double-Blind Method | 2 | 2024 | 12427 | 0.040 |
Why?
|
Echocardiography | 2 | 2024 | 4981 | 0.040 |
Why?
|
Cross-Sectional Studies | 3 | 2019 | 25942 | 0.040 |
Why?
|
Ventricular Function, Left | 2 | 2023 | 3880 | 0.040 |
Why?
|
Heart Failure | 1 | 2023 | 11847 | 0.040 |
Why?
|
Endothelial Cells | 2 | 2024 | 3539 | 0.040 |
Why?
|
Chloroquine | 1 | 2020 | 277 | 0.040 |
Why?
|
Time Factors | 3 | 2021 | 40165 | 0.040 |
Why?
|
Cohort Studies | 2 | 2019 | 41335 | 0.040 |
Why?
|
Takotsubo Cardiomyopathy | 1 | 2020 | 124 | 0.040 |
Why?
|
Stroke Volume | 2 | 2023 | 5523 | 0.040 |
Why?
|
Epigenomics | 1 | 2024 | 936 | 0.040 |
Why?
|
Cross-Over Studies | 1 | 2014 | 2061 | 0.040 |
Why?
|
Adenosine Monophosphate | 1 | 2020 | 283 | 0.040 |
Why?
|
Cholesterol | 2 | 2019 | 2924 | 0.040 |
Why?
|
Islets of Langerhans | 1 | 2024 | 1345 | 0.040 |
Why?
|
Alanine | 1 | 2020 | 606 | 0.040 |
Why?
|
Diet | 1 | 2015 | 8010 | 0.040 |
Why?
|
Sphingosine | 1 | 2019 | 308 | 0.040 |
Why?
|
Young Adult | 4 | 2019 | 58741 | 0.040 |
Why?
|
Adipocytes | 1 | 2024 | 1179 | 0.040 |
Why?
|
Lysophospholipids | 1 | 2019 | 339 | 0.030 |
Why?
|
Plasma | 1 | 2020 | 584 | 0.030 |
Why?
|
Diabetic Nephropathies | 1 | 2024 | 988 | 0.030 |
Why?
|
Virus Internalization | 1 | 2020 | 494 | 0.030 |
Why?
|
Prevalence | 1 | 2013 | 15687 | 0.030 |
Why?
|
Platelet Aggregation | 1 | 2019 | 805 | 0.030 |
Why?
|
Hydroxychloroquine | 1 | 2020 | 427 | 0.030 |
Why?
|
Multifactorial Inheritance | 1 | 2024 | 1365 | 0.030 |
Why?
|
Portugal | 1 | 2015 | 91 | 0.030 |
Why?
|
Butter | 1 | 2015 | 22 | 0.030 |
Why?
|
Homeostasis | 2 | 2019 | 3306 | 0.030 |
Why?
|
Adult | 6 | 2024 | 219994 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 3 | 2019 | 36290 | 0.030 |
Why?
|
Soybean Oil | 1 | 2015 | 139 | 0.030 |
Why?
|
Odds Ratio | 2 | 2017 | 9716 | 0.030 |
Why?
|
Asymptomatic Diseases | 1 | 2017 | 587 | 0.030 |
Why?
|
Nutrition Assessment | 1 | 2017 | 727 | 0.030 |
Why?
|
Echocardiography, Three-Dimensional | 1 | 2019 | 613 | 0.030 |
Why?
|
Fatty Acids, Omega-6 | 1 | 2015 | 227 | 0.030 |
Why?
|
Antimalarials | 1 | 2020 | 906 | 0.030 |
Why?
|
Metformin | 1 | 2021 | 912 | 0.030 |
Why?
|
Infant, Newborn | 1 | 2013 | 26181 | 0.030 |
Why?
|
Single-Cell Analysis | 1 | 2024 | 2380 | 0.030 |
Why?
|
Muscle Strength | 1 | 2017 | 619 | 0.030 |
Why?
|
Population Growth | 1 | 2012 | 50 | 0.030 |
Why?
|
Chromatin | 1 | 2024 | 2938 | 0.030 |
Why?
|
Neoplasms | 1 | 2020 | 22072 | 0.020 |
Why?
|
Exercise Tolerance | 1 | 2017 | 830 | 0.020 |
Why?
|
Fishes | 1 | 2015 | 601 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2019 | 4899 | 0.020 |
Why?
|
Antioxidants | 1 | 2019 | 1667 | 0.020 |
Why?
|
Infant | 1 | 2013 | 36060 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 2017 | 12159 | 0.020 |
Why?
|
Blood Chemical Analysis | 1 | 2012 | 437 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2021 | 6498 | 0.020 |
Why?
|
Absorptiometry, Photon | 1 | 2017 | 1736 | 0.020 |
Why?
|
Species Specificity | 1 | 2015 | 2418 | 0.020 |
Why?
|
Child, Preschool | 1 | 2013 | 42063 | 0.020 |
Why?
|
Safety | 1 | 2015 | 1148 | 0.020 |
Why?
|
C-Peptide | 1 | 2011 | 433 | 0.020 |
Why?
|
Geriatric Assessment | 1 | 2017 | 1405 | 0.020 |
Why?
|
Exercise Test | 1 | 2017 | 2128 | 0.020 |
Why?
|
Adolescent | 2 | 2015 | 87810 | 0.020 |
Why?
|
Nutritional Status | 1 | 2017 | 1607 | 0.020 |
Why?
|
Oxidative Stress | 1 | 2019 | 3106 | 0.020 |
Why?
|
Animals | 3 | 2019 | 167963 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2020 | 3061 | 0.020 |
Why?
|
Glucose | 1 | 2019 | 4351 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2023 | 15289 | 0.020 |
Why?
|
Adiposity | 1 | 2017 | 1858 | 0.020 |
Why?
|
Heart Ventricles | 1 | 2019 | 3811 | 0.020 |
Why?
|
Fatty Acids | 1 | 2015 | 1804 | 0.020 |
Why?
|
Hospitalization | 2 | 2019 | 10790 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2023 | 10344 | 0.020 |
Why?
|
Child | 1 | 2013 | 79806 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2012 | 15840 | 0.010 |
Why?
|
Insulin-Secreting Cells | 1 | 2011 | 907 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2011 | 6238 | 0.010 |
Why?
|
Up-Regulation | 1 | 2011 | 4122 | 0.010 |
Why?
|
Acute Disease | 1 | 2012 | 7269 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8624 | 0.010 |
Why?
|
Comorbidity | 1 | 2012 | 10551 | 0.010 |
Why?
|
Signal Transduction | 1 | 2019 | 23376 | 0.010 |
Why?
|
Incidence | 1 | 2012 | 21392 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2015 | 20509 | 0.010 |
Why?
|
Prognosis | 1 | 2012 | 29658 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2015 | 80372 | 0.000 |
Why?
|